Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

SGYP 3.75 +0.12 (3.31%)
price chart
Synergy Pharmaceuticals Progresses with Mid-Stage Candidate - Analyst Blog
Synergy Pharma enrolled 260 patients suffering from OIC who have less than 3 spontaneous bowel movements (SBMs) per week and have experienced constipation-related symptoms.
Synergy Pharmaceuticals Progresses with Mid-Stage Candidate  Yahoo News
Related articles »  
Traders Recap - Earthlink Holdings (ELNK), Synergy Pharmaceuticals Inc ...
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) declared its financial results and business update for the 4th quarter and the year ended 31st December, 2013.
Related articles »  
Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 ...
NEW YORK, Jul 14, 2014 (BUSINESS WIRE) -- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has reached the halfway mark for total enrollment in the first pivotal phase 3 trial of plecanatide in patients with chronic idiopathic ...
Synergy Pharma Reaches Halfway Mark For 1st Pivotal Phase 3 Trial Of ...  RTT News
Related articles »  
Morning Briefing on Biotech Stocks -- Research on Dynavax Technologies ...
Sign up today to read free research on DVAX at: http://www.investor-edge.com/4432-DVAX-02Jul2014.pdf Synergy Pharmaceuticals Inc.'s stock advanced 1.72%, to close the day at $4.14. The stock recorded a trading volume of 0.92 million shares, below its ...
Related articles »  
Synergy Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with ...
NEW YORK, Jul 08, 2014 (BUSINESS WIRE) -- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S.
Related articles »  
Synergy Pharmaceuticals Plecanatide to Move into Phase III
Apart from the IBS-C indication, Synergy Pharma is developing plecanatide for the chronic idiopathic constipation (CIC) indication as well.
Synergy Pharmaceuticals' Plecanatide to Move into Phase III  Yahoo News
Traders Recap - Synergy Pharmaceuticals Inc (SGYP), Sunstone Hotel Investors ...  Techsonian (press release)
Related articles »  
News Recap: Synergy Pharmaceuticals Inc (SGYP), Cumulus Media Inc (CMLS ...
Manhattan, NY- July 16, 2014 - (Techsonian) - Synergy Pharmaceuticals Inc (NASDAQ:SGYP) declared its financial results and business update for the 4th quarter and the year ended 31st December, 2013.
Synergy Pharmaceuticals Sees Significant Increase in Short Interest (SGYP)  Mideast Time
Related articles »  
Stocks in the Spotlight: CTI BioPharma (CTIC), Synergy Pharmaceuticals Inc ...
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) revealed the appointment of Paul Eng, Ph.D., as Senior Vice President, Drug Development.
Related articles »  
Short Interest in Synergy Pharmaceuticals Decreases By 4.6% (SGYP)
Analysts expect that Synergy Pharmaceuticals will post $-0.88 EPS for the current fiscal year. Synergy Pharmaceuticals, Inc is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (NASDAQ:SGYP), disorders ...
Synergy Pharmaceuticals Upgraded by Zacks to Outperform (SGYP)  Ticker Report
Related articles »  
Synergy Pharmaceuticals's Positive Rating Reaffirmed at Aegis (SGYP)
Synergy Pharmaceuticals Inc logo Synergy Pharmaceuticals (NASDAQ:SGYP)'s stock had its �positive� rating reaffirmed by Aegis in a research note issued on Tuesday.